An investigation of antitumor effectiveness using M-VAC/CaG prediction system in neoadjuvant chemotherapy for muscle invasive bladder cancer.
Phase 2
- Conditions
- Muscle-invasive bladder cancer
- Registration Number
- JPRN-UMIN000019902
- Lead Sponsor
- Department of Urology, Iwate Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1) The case with serious complications 2) The case with active double cancer 3) The case with pregnancy, lactation or possibility of pregnancy 4) The case with drug allergy for G-CSF 5) The case with drug allergy for M-VAC or CaG 6) The case without the selection criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoints of this study are accuracy and efficacy of prediction systems, proportion of achieving significant tumor shrinking (>60%) by either or both of the two regimens with intention-to-treat compared with that of historical controls.
- Secondary Outcome Measures
Name Time Method The secondary endpoint is the overall survival between the patients of this prospective study and the historical controls.